Research Triangle Park, NC, December 8, 2010 – Two Catalent scientists, Dr. Lei Mao, Project Director, Senior Scientist in the Pulmonary and Nasal Research and Development, and Dr. Craig J. Davies-Cutting, Director, Research and Development, will have prominent roles leading this year’s Drug Delivery to the Lungs 21 (DDL21) conference. The meeting will be held at the Edinburgh International Conference Centre in Edinburgh, Scotland, UK on December 8-10, 2010.
Dr Davies-Cutting will chair a session titled “Advances in Formulation and Analytical Science.” His session will explore leading topics such as ventilator aerosol delivery systems (VADS), electrostatic charge and the use of nuclear magnetic resonance (NMR) in pressurized metered dose inhaler (pMDI) development. This session will feature Dr. Jolyon Mitchell of Trudell Medical International, Dr. Daniela Traini of the University of Sydney and Dr. Dave Martin of AstraZeneca.
Dr. Mao will present, “Controlling Product Through Predication of Formulation Concentration During Pressurized Metered Dose Inhaler (pMDI) Manufacturing Processes – A Comparison of Theoretical and Empirical Data.” The presentation will reveal the mathematical equation Dr. Mao and his team derived to help predict the concentration of propellant-based aerosol formulations known to change during pMDI batch production processes. The mathematical model helps to establish the correlation of the changes between can content and vessel head space that occur during filling to help control the process more effectively.
Dr. Davies-Cutting is based at Catalent’s facility in Research Triangle Park, NC where he is responsible for Pulmonary & Nasal Product Development activities along with Sterile Product Development and Analytical Research & Development. He has 23 years of pharmaceutical industry experience of which 18 years have been in the inhalation arena.
Dr. Mao is responsible for the Pulmonary & Nasal Product Development activities at Catalent’s site in Research Triangle Park, NC. Prior to joining Catalent in 2008, Dr. Mao led an inhalation development team at Vectura plc, UK where he held Senior Scientist, Principal Scientist and Team Leader positions. He has more than 15 years of experience in the inhalation industry, with extensive knowledge in dry powder inhaler, metered dose inhaler, nebulizer and nasal product development. Dr. Mao is an inventor of 14 patents granted worldwide and has been published in more than 25 peer reviewed journals and conference proceedings.
For more information on Catalent’s drug delivery systems and expertise in inhaled delivery, go to http://www.catalent.com/offerings/drug-delivery.
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,000 people at 29 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
